Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pingvakatin
- Development stage
- Phase 1
- Lead developer
- Shanghai Institute of Materia Medica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pingvakatin (DC371739) is an orally bioavailable small molecule inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), developed by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences. It is being investigated for the treatment of hypercholesterolemia and mixed dyslipidemia. By inhibiting PCSK9, the drug prevents the degradation of low-density lipoprotein receptors (LDLR) on the surface of liver cells, which enhances the liver's ability to clear LDL cholesterol from the bloodstream. As an oral agent, it offers a potential alternative to injectable PCSK9 monoclonal antibodies.
- Other names
- pingvakatin
02
Targets
ANGPTL3 (Angiopoietin-like protein 3)HNF1A (Hepatocyte nuclear factor 1-alpha)PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on pingvakatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pingvakatin.